News briefing: Dewpoint scores another Big Pharma deal, this time with Pfizer; Kite joins forces with Oxford BioTherapeutics
Over the last 13 months, Dewpoint Therapeutics has scored big partnerships with Bayer and Merck, aiming to pioneer a new field of biology called biomolecular condensates. On Wednesday, the biotech reeled in another big pharma deal.
Dewpoint agreed to a research collaboration with Pfizer on Wednesday for the development of therapies for myotonic dystrophy type 1, a rare genetic disorder. The deal can be worth up to $239 million when accounting for all milestones.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.